Physiomics PLC Conference presentation
22 Junio 2020 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
22 June 2020
22 June 2020
Physiomics plc
("Physiomics") or ("the Company")
Conference presentation
Physiomics to present on dual immuno-therapy at AACR 2020
Virtual Meeting II
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it is
participating in the American Academy of Cancer Research ("AACR")
Annual Meeting 2020, being held as a virtual event.
The Company will be presenting on a new version of its Virtual
Tumour(TM) model, which is able to simulate the efficacy of dual
immuno-therapy regimens. The model was originally developed as part
of a client project.
The Company will be presenting an original poster in the session
"LBPO.IM02 - Late-Breaking Research: Immunology 2", scheduled for
22 June 2020 at 9.00 a.m. - 6.00 p.m. EDT (Eastern Daylight Time).
The poster is titled "Optimising dual immuno-oncology combinations
with Virtual Tumour" (Abstract # LB-392). The session will include
live interactions and the poster will remain available for viewing
by registered attendees for at least three months after the virtual
meeting.
Over recent years, driven by a number of actual client projects,
we have extended our Virtual Tumour(TM) technology from a tool to
predict the effect of drugs directly targeting tumour growth
inhibition, into one that can also simulate the effects of
immuno-therapies. This latest release of the Virtual Tumour(TM)
immune module can simulate the effects of established immune
checkpoints (e.g. anti PD-(L)1) in combination with agents
targeting components of the innate immune system, such as myeloid
derived suppressor cells (e.g. complement inhibitors).
A copy of the poster will be made available on Physiomics'
website at 9.00 a.m. EDT (2.00 p.m. BST) at:
https://www.physiomics.co.uk/resources .
According to AACR, it is the oldest and largest scientific
organisation in the world, focused on every aspect of high-quality,
innovative cancer research. Its annual conference is usually
attended by representatives from public and private sector
organisations, from the very small to the largest global players,
with over 20,000 participants attending in 2019. This year, as a
virtual event, access will be free to everyone who registers, and
presentations may therefore reach a wider audience than usual.
More information about the conference may be found using the
following link:
https://www.aacr.org/meeting/aacr-annual-meeting-2020 .
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions. The Company's Virtual Tumour(TM)
technology uses computer modelling to predict the effects of cancer
drugs and treatments to improve the success rate of drug discovery
and development projects while reducing time and cost. The
predictive capability of Physiomics' technologies have been
confirmed by over 70 projects, involving over 30 targets and 60
drugs, and has worked with clients such as Merck KGaA, Merck &
Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGZGZVVMVGGZM
(END) Dow Jones Newswires
June 22, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024